While it seems management may have been blindsided, there seems...

While it seems management may have been blindsided, there seems to be two developments on the 23rd of September 2021 that raises questions:

First, TLX released to the market the announcement titled "FDA Extends New Drug Application Review Period for Illuccix". On the same day, Novartis announces to the market a license agreement with Theragnostics to develop and commercialize radiopharmaceuticals using its Gallium-68 technology platform. Did Novartis have anything to do with the delay of TLX's NDA application?

In other news, Novartis today announced a collaboration with Lantheus to include Pylarify in their clinical trials for Pluvicto for the selection of patients with prostate cancer. This will no doubt further reduce market share for Illuccix.

all in my opinion, dyor

References:
https://hotcopper.com.au/threads/ann-fda-extends-new-drug-application-review-period-for-illuccix.6302516/
https://theragnostics.com/theragnostics-announces-licensing-agreement-for-development-and-commercialization-of-one-step-pet-radiopharmaceuticals/
https://www.globenewswire.com/news-release/2022/03/29/2411848/0/en/Lantheus-Announces-Collaboration-to-Support-Prostate-Cancer-Clinical-Development.html